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Precis 39 
HBD-1 and -2 were consistently expressed in fungal keratitis samples. While HBD-3, -9, S100A7, 40 
and LL-37 showed variable expression pattern. The results indicate the therapeutic potential of 41 
recombinant or linear AMPs against fungal pathogens.   42 
 43 
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ABSTRACT 64 
 65 
Background: Fungal keratitis (FK) is the leading cause of unilateral blindness in the developing 66 
world. Antimicrobial peptides (AMPs) have been shown to play an important role on human ocular 67 
surface (OS) during bacterial, viral, and protozoan infections. Here, our aim was to profile a spectrum 68 
of AMPs in corneal tissue from FK patients with active infection and after healing.  69 
 70 
Methods: OS samples were collected from patients at presentation by impression cytology and 71 
scraping. Corneal button specimens were collected from patients undergoing therapeutic penetrating 72 
keratoplasty for management of severe FK or healed keratitis. Gene expression of human beta-73 
defensin (HBD)-1, -2, -3 and -9, S100A7, and LL-37 was determined by quantitative real-time 74 
polymerase chain reaction (qPCR). 75 
 76 
Results: Messenger RNA expression (mRNA) for all AMPs was shown to be significantly 77 
upregulated in FK samples. Levels of HBD-1 and -2 mRNA were found to be elevated in 18/20 FK 78 
samples. Whereas mRNA for HBD-3 and S100A7 was upregulated in 11/20 and HBD9 was increased 79 
in 15/20 FK samples. LL-37 mRNA showed moderate upregulation in 7/20 FK samples compared to 80 
controls. In healed scar samples, mRNA of all AMPs was found to be low and matching the levels in 81 
controls.  82 
 83 
Conclusion: AMP expression is a consistent feature of FK, but not all AMPs are equally expressed. 84 
HBD-1 and -2 are most consistently expressed and LL-37 the least, suggesting some specificity of 85 
AMP expression related to FK. This information will be useful in developing strategiesThe outcomes 86 
will form the basis to use HBDs sequence as a template for designing FK-specific peptide 87 
therapeutics for use of AMPs in treating FK. 88 
 89 
 90 
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 92 
INTRODUCTION 93 
Fungal keratitis (FK) is the commonest cause of corneal blindness in developing world. The 94 
prevalence of FK has been linked to geographical climate1. In India, it was estimated that up to 35% 95 
of patients that present with infective keratitis were culture positive for mycotic organisms2 3. The 96 
principal risk factor for FK in more than 70% of these cases was reported to be vegetative ocular 97 
injury3. Increasing reports of FK cases from countries with temperate conditions have added to the 98 
infection-related incidence of blindness globally4-6. In developed countries, incidence  of FK cases is 99 
also increasing and mainly associated with contact-lens use and ocular trauma7. In the United 100 
Kingdom, FK incidence increased from 4.5 cases per year (between 1994 to 2006) to 14 cases per 101 
year (between 2007 to 2014)5. In the midwestern region of the United States, 16% cases of infective 102 
keratitis (between 1999 to 2013) were identified as FK with poor healing and major complications8. 103 
The socio-economic impact of this disease has been significantly high because it predominantly 104 
affects individuals in working age group9-11. Clinical features of FK often overlap with bacterial 105 
keratitis and frequently these are difficult to diagnose12. Poor penetration and lack of effective anti-106 
fungal agents has further compounded the problem of FK13-15. Therefore, to seek alternative therapies, 107 
current research in this field has been mainly focused on understanding of mechanisms by which host 108 
immunity responds to fungi and yeast. 109 
 110 
Antimicrobial peptides (AMPs) are naturally occurring host defence proteins with broad-spectrum 111 
antimicrobial activity against bacteria, fungi and viruses16-18. They play an important role in innate 112 
immunity and are known to be expressed at epithelial surfaces of the human body. We were the first 113 
group to provide evidence for the presence of AMPs at the ocular surface19 and profiled the range of 114 
AMPs (human beta-defensin (HBD)-1 to 3, HBD-9 and cathelicidin (LL-37)) at the human ocular 115 
surface and their expression in corneal infections20-22. We also elucidated the signaling mechanisms 116 
involved in RNase-7 and HBD-9 secretion from human corneal epithelial cells23 24.  117 
 118 
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Antifungal activity of AMPs (such as defensins and cathelicidin) is well known25-27 through animal 119 
studies, but the profile of human AMPs at the ocular surface in response to fungal infections has not 120 
been elucidated. In this study, we profiled the gene expression of well-characterised human AMPs in 121 
corneal specimens during active phase of infection and after healing.  122 
 123 
 124 
MATERIALS AND METHODS 125 
Research was conducted in accordance with the tenets of the Declaration of Helsinki. Study was 126 
approved by the Institutional Review Board of Hyderabad Eye Research Foundation (Ethics code: 127 
2016-13-CD-13), L.V. Prasad Eye Institute (LVPEI), Bhubaneswar, India. Informed consent was 128 
obtained from all patients prior to collection of samples, which included scrapes/ impression cytology 129 
from patients with active fungal keratitis, corneal buttons (part of) from patients that were subjected 130 
to therapeutic penetrating keratoplasty (tPK) for fungal keratitis not responding to medical 131 
management and corneal tissue from patients with non-inflammatory corneal scar that underwent 132 
optical penetrating keratoplasty (controls).   133 
 134 
Study design: 135 
A prospective consecutive case series of patients with fungal keratitis  136 
Inclusion criteria  137 
• Patients diagnosed clinically as suffering from FK and confirmed by standard microbiology 138 
and/or histopathology techniques. 139 
• Patients with active FK who had received no treatment or were unresponsive to treatment. 140 
• Patients of 18 years of age or older. 141 
• Patients able to give informed consent. 142 
 143 
Exclusion criteria  144 
• Patients with mixed fungal and bacterial keratitis 145 
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• Patients on topical or systemic steroid treatment 146 
• Patients on immunosuppressive treatment or known to be immunosuppressed 147 
• Patients presenting with non-infectious causes of ocular inflammation 148 
• Patients with viral keratitis 149 
 150 
Sample collection:  151 
Corneal scrapes were collected using standard techniques with sterile Bard Parker blade number1528. 152 
Impression cytology (IC) was performed to collect superficial layers of corneal epithelium using 153 
cellulose acetate ester discs, as previously reported20. Part of corneal button (CB) from patients 154 
undergoing therapeutic or optical PK was collected in 600 μL RNAlater solution (Qiagen, Germany) 155 
on ice and then transferred to buffer RLT prior to storage at -80oC.  156 
 157 
Total RNA isolation and Reverse transcription: 158 
Corneal tissue in RLT buffer was homogenized using a tissue ruptor (Qiagen, Germany) for 60 159 
seconds on ice. Total RNA was isolated from CB, IC samples, and corneal scrapes using RNeasy 160 
Mini Kit (catalog No. 74104; Qiagen, Germany) according to manufacturers’ instructions, including 161 
the optional DNase step. Isolated RNA was quantitated using Biospectrophotometer (Eppendorf, 162 
Germany). 200ng total RNA was reverse transcribed to complementary deoxyribonucleic acid 163 
(cDNA) using Eurogentec Reverse Transcription Core Kit (RT-RTCK-03, Eurogentec, Belgium) as 164 
per manufacturers’ instructions. No RT-enzyme control samples were also prepared.  165 
 166 
Quantitative real-time polymerase chain reaction (qPCR): 167 
Quantitative PCR was conducted for selected AMPs (Table 1) using Taqman probe chemistry. 168 
Taqman assays specific to AMPs, hypoxanthine-guanine phosphoribosyltransferase [HPRT] and 169 
appropriate controls were run in duplicate in a 96-well plate in the Mx3005p real-time PCR 170 
instrument (Agilent technologies, Milton Keynes, UK). Briefly, template cDNA was initially diluted 171 
to 1 in 5 using nuclease-free water. A 20 L reaction mix was prepared for each well as per 172 
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instructions for Taqman Gene Expression mastermix (Applied Biosystems, Waltham, MA). Each 173 
reaction mixture comprised of 10 L of 2x mastermix, 1 L of 20x taqman assay, 5 L of diluted 174 
cDNA and 4L of nuclease-free water. All probes used in this study were template specific. However, 175 
to rule out any genomic amplification, appropriate no-RT controls were also included against each 176 
gene probe. CT values were acquired using MxPro Software version 5.0 and further analysed by delta-177 
delta CT comparative method
29.  178 
 179 
Statistical analysis: 180 
The qPCR data was subjected to statistical analysis using Prism version 8.1 software (GraphPad 181 
software, San Diego, CA) with alpha set at p  0.05. Due to differences in the group size, we 182 
performed unpaired Welch’s unequal variances t-test for control versus active and active versus 183 
healed groups.  184 
 185 
 186 
RESULTS 187 
As shown in table 2, a total 26 samples were collected. These included a part of CB (n=17), scrapings 188 
(n=5) and IC (n=4). Of CB specimens, 3 were grouped as ‘controls’ (patients’ that required optical 189 
PK for management of non-inflammatory corneal scar); 11 were grouped as ‘active FK’ (patients’ 190 
with severe FK that required tPK) and 3 were grouped as ‘healed’ keratitis (patients’ that required PK 191 
post-medical management for FK). Table 2 mentions the day of collection of corneal button samples 192 
(Column no.8). CB tissue of active FK was collected between day 1 to 30 from the day of 193 
presentation and those from the healed group between 6-12 months from the day of presentation. 194 
Scraping and IC samples (5+4) were also included under the group of ‘active FK’ and were collected 195 
between day 0 to 3 from the day of presentation, before commencement of antifungal therapy. In 196 
total, we studied n=3 in controls; n=20 in active FK and n=3 in healed group. As shown in table 2, 197 
final diagnosis was based on positive growth of fungi in cultures from corneal scrapings and/or on 198 
histopathology evaluation. Of n=23 cases of fungal keratitis, 3 samples showed no growth on culture, 199 
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however, they were later confirmed as fungal by aetiology on histological evaluation. In addition, 200 
2/23 patients presented with a perforation or an impending perforation were not scraped but later 201 
confirmed as FK, on histopathology. A range of fungi were identified but fusarium species was the 202 
most common (Table 2). 203 
 204 
Variable expression of AMPs in active FK and healed samples 205 
HBD-1, -2, and -9 and LL-37 were shown to be constitutively expressed in all control samples, 206 
whereas mRNAs for HBD-3 and S100A7 were expressed at a very low level in controls. As shown in 207 
figure 1, all AMPs were significantly increased during active FK. Notably, in healed samples, their 208 
mRNA expression was found to be at a similar level to those in controls. Levels of mRNA expression 209 
is denoted as mean  standard deviation.  210 
 211 
HBD-1 and -2 mRNA were significantly increased in 18/20 active FK samples. HBD-1 was 212 
upregulated by 12.03  9.06 fold (p<0.0001) and HBD-2 was elevated by 254.7  335.82 fold 213 
(p=0.003) in FK compared to controls. However, in healed samples, these levels were significantly 214 
reduced with HBD-1 at 2.19  1.72 fold (p=0.0003) and HBD-2 at 0.23  0.28 fold (p=0.003) 215 
compared to active FK.  216 
 217 
The level of HBD-3 and S100A7 mRNAs were elevated in 11/20 FK samples, whereas HBD9 mRNA 218 
was upregulated (> 2-fold) in 15/20 FK samples. HBD-3 was increased by 5.54  8.28 fold (p=0.007) 219 
and HBD-9 was elevated by 31.83  51.15 fold (p=0.018) in FK. Similar to other defensins, HBD-3 220 
and HBD-9 also showed baseline expression in healed samples with levels at 0.01  0.02 fold 221 
(p=0.007) and 0.51  0.40 fold (p=0.013), respectively. S100A7 mRNA expression was shown to be 222 
increased by 61.89  95.73 fold (p=0.009) in FK samples compared to controls. Whereas in healed 223 
samples, mRNA levels for S100A7 were reduced to 0.19  0.34 fold (p=0.009) compared to FK.  224 
 225 
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Of all AMPs, LL-37 mRNA was moderately increased in FK showing elevated expression (4.05  226 
7.41 fold; p=0.047) only in 7/20 samples. In healed samples, LL-37 was expressed at low levels (1.16 227 
 1.01 fold; not significant) matching the mRNA levels in controls. 228 
DISCUSSION 229 
AMPs have attracted special attention as potential therapy for microbial infections due to their unique 230 
mode of action compared to available antimicrobial therapies30. In the last two decades, we and others 231 
have extensively demonstrated an essential role of human AMPs in microbial keratitis17 19-23 31-33. In 232 
corneal epithelial cells, expression of HBD-2, HBD-3 and LL-37 were shown to be significantly 233 
elevated in response to infection with Fusarium solani34 and Candida albicans35, respectively. 234 
Elevated levels of cytokines and other innate immune receptors was previously demonstrated in 235 
human corneal specimen from patients with Aspergillus flavus and Fusarium solani infection 36. 236 
Moreover, increased susceptibility to corneal infections by Aspergillus fumigatus, Fusarium solani 237 
and Candida albicans was previously demonstrated in mice deficient in cathelin-related antimicrobial 238 
peptide (CRAMP) and murine -defensins (mBD-1 to -4)37 38. 239 
 240 
In this study, we demonstrated an increased pattern of AMPs (HBD-1 to -3, HBD-9, S100A7 and LL-241 
37) expression in corneal specimen during active infection. Notably, in healed specimen, mRNA of 242 
all AMPs was found to be at a basal level. A similar phenomenon has been noted in our previous 243 
demonstration of HBD-3 and HBD-9 mRNA levels in OS specimen collected during active bacterial 244 
keratitis and following complete healing31. Moreover, in an animal model of Candida albicans 245 
keratitis, CRAMP and -defensins (mBD-1 and -2) have demonstrated a variable expression at the 246 
onset of disease but returned to their normal level upon healing at day 7 post-infection38. In Fusarium 247 
solani keratitis mouse model, mBD-3, mBD-4, mBD-14 and CRAMP were shown to be significantly 248 
increased by day 3 post-infection, which then started to decrease with reduction in disease severity 249 
reaching to baseline upon healing37. From above studies, it could be inferred that rapid normalisation 250 
of AMPs expression following healing occurs and is likely to be of importance considering the fact 251 
that high levels of AMPs could elicit toxic responses on ocular surface.  252 
 10 
 253 
Previously we have demonstrated a significant downregulation of HBD9 expression in specimen from 254 
patients with bacterial keratitis, acanthamoeba keratitis, viral keratitis and dry-eye disease20. 255 
Interestingly, in current study, we have noted an elevated pattern of HBD9 expression in active FK 256 
samples. This unique response of HBD9 during fungal infection suggest a potential anti-fungal 257 
function of this AMP. We have generated the recombinant protein of HBD9 using E. coli expression 258 
system and demonstrated that both recombinant HBD9 protein and its full-length synthetic linear 259 
peptide were unstable, which was attributed to its proline rich C-terminus. Failure to keep the protein 260 
or its linear peptide in solution has thus far prevented us to test the antimicrobial efficacy of HBD9 261 
against disease-causing pathogens (unpublished observations). 262 
 263 
S100A7 was first isolated from skin of Psoriasis patients hence it is also known as Psoriasin39. 264 
S100A7 has been shown to express constitutively in different regions of anterior segment of the eye40. 265 
Interestingly, cysteine-reduced form of S100A7 protein has been previously shown to exhibit potent 266 
antifungal activity against dermatophytes and filamentous fungi41. Whereas both native and reduced 267 
forms of S100A7 showed activity against the yeast, C. albicans41. A previous study has demonstrated 268 
the increased levels of S100A7 in vaginal biopsies from patients with C. albicans vulvovaginitis42. 269 
Similar increased levels of S100A7 were also noted in this study. Further research using gene 270 
knockout experiments would highlight the importance of S100A7 in host defense to fungal infections 271 
at the ocular surface.  272 
 273 
Although FK is slowly progressive compared to bacterial keratitis, the rate of corneal perforation has 274 
been reported to be high in FK cases43. AMPs are potent chemo attractants and capable of eliciting 275 
adaptive immunity30. Thus, in addition to direct killing of microbes, increased level of AMPs during 276 
FK could potentially increase neutrophil infiltration, which might contribute towards tissue damage, 277 
melting, and scarring. A recent report has demonstrated that deficiency of CRAMP and mBD-3 and -4 278 
increased the susceptibility to F. solani keratitis and led to excessive infiltration of neutrophils which 279 
was attributed  to high levels of KC (a neutrophil chemokine) in corneal tissue37. Similarly, in C. 280 
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albicans keratitis model, deletion of CRAMP was also shown to increase yeast burden, neutrophil 281 
recruitment and levels of IL-1 and MIP-244. In stark contrast to keratitis model, severity of C. 282 
albicans infection in oral mucosa in mBD-1 knockout mice have been associated with low neutrophil 283 
recruitment and reduced levels of IL-1, KC, IL-17A and IL-17F45. In mice cornea, the specific 284 
function of neutrophil derived calprotectin (S100A8/A9) in clearance of A. fumigatus has been 285 
demonstrated. Unlike cationic AMPs, calprotectin was shown to exhibit antifungal activity via 286 
chelation of zinc and manganese which retards A. fumigatus growth46.  287 
 288 
Our results corroborate previous studies on AMP regulation during fungal infection in animals. This 289 
further implicates a pivotal role for AMPs in OS defense against fungal pathogens. However, their 290 
diverse function in modulation of neutrophil infiltration and inflammation in cornea and other 291 
mucosal sites during infection still remains unclear. Though this is the first study on AMPs in human 292 
FK further studies are highly warranted to understand the mechanisms of immune activation of AMPs 293 
during FK. The limitation of this study was that it only involved assessment of gene expression of 294 
AMPs in active and healed groups. A follow-up study addressing the cellular source of these AMPs in 295 
active FK samples will further enhance the understanding of function of key AMPs towards 296 
fungi/yeast.  297 
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Figure legend  465 
 466 
Figure 1. Gene expression of antimicrobial peptides in corneal tissue from patients with fungal 467 
keratitis. Relative fold change of A) HBD1, B) HBD2, C) HBD3, D) HBD9, E) S100A7 and F) LL-468 
37 in control, active FK and healed groups. Data points represent individual patients in each group. 469 
Student’s t-test with Welch’s correction was performed to compare control vs active FK and active 470 
FK vs healed with p  0.05 denotes statistical significance.  471 
 472 
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Tables 474 
 475 
 476 
Table 1. List of TaqMan probes  477 
 478 
 479 
Gene name Assay ID 
DEFB1 (HBD-1) Hs00608345_m1 
DEFB4 (HBD-2) Hs00823638_m1 
DEFB103(HBD-3) Hs00218678_m1 
DEFB109(HBD-9) Hs002760065_g1 
S100A7 Hs00961622_m1 
CAMP (LL-37) Hs00189038_m1 
HPRT1 4325801 
 480 
 481 
 482 
 483 
484 
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 485 
Table 2. Clinical diagnosis and laboratory results 486 
 487 
 488 
No. 
Age 
/Sex 
Clinical 
diagnosis 
Size 
of 
inf.(mm) 
Scr- 
C/S 
Sam
ple 
used 
Outcome
/ 
Keratopl
asty 
Pres 
to 
Ker 
Histopathology 
findings 
CB- 
C/S 
1. 
36 
/M 
Corneal 
scar 
NA NA CB NA/Y 11m 
Vascularised 
corneal scar 
NA 
2. 
38 
/F 
Corneal 
scar, post 
trauma 
NA NA CB NA/Y 
5 
yrs 
Non 
inflammatory 
corneal scar 
NA 
3. 
19 
/M 
Corneal 
scar since 
childhood 
NA NA CB NA/Y 6m 
Non 
inflammatory 
corneal scar 
NA 
 
 
 
4. 
86 
/M 
Microbial 
Keratitis 
3.5x2.5 
unid. 
hyaline 
fungus  
Scra
pe 
Resolved 
keratitis 
/ND 
NA NA NA 
5. 
86 
/M 
Microbial 
Keratitis 
3.5x2.5 
unid. 
hyaline 
fungus  
Imp 
Resolved 
keratitis/ 
ND 
NA NA NA 
6. 
30 
/F 
Corneal 
ulcer 
TCI 
Aspergillus 
spp.  
Scra
pe 
Failed to 
resolve/
Y 
30d 
Fungal corneal 
ulcer 
NG 
7. 
30 
/F 
Corneal 
ulcer 
TCI 
Aspergillus 
spp.  
Imp 
Failed to 
resolve/
Y 
30d 
Fungal corneal 
ulcer 
NG 
8. 
22 
/F 
Corneal 
ulcer 
2x1.5 NG 
Scra
pe 
Partially 
resolved 
/Y 
30d 
Fungal keratitis 
with yeast like 
spores 
NG 
9. 
36 
/M 
Fungal 
Keratitis 
4x4.5 
Fusarium 
spp.  
Scra
pe 
Resolved 
keratitis 
/ND 
NA NA NA 
10. 
69 
/M 
Perforated 
Corneal 
ulcer with 
hypopyon 
TCI 
Lasiodiplo
dia spp.  
Scra
pe 
Failed to 
resolve/
Y 
18d 
Fungal corneal 
ulcer 
NG 
11. 
27 
/F 
Microbial 
Keratitis 
3.5x2 
Fusarium 
spp.  
Imp LFU NA NA NA 
12. 
31 
/M 
Corneal 
ulcer with 
hypopyon 
TCI 
Aspergillus 
spp.  
Imp 
Resolved 
keratitis/
Y 
6m Corneal scar NG 
13. 
75 
/M 
Fungal 
Keratitis 
5x2 
Acremoniu
m spp.  
CB 
Failed to 
resolve/
Y 
30d 
Fungal Corneal 
ulcer 
NG 
14. 
39 
/M 
Microbial 
Keratitis 
5.5 
Fusarium 
spp.  
CB 
Failed to 
resolve/
Y 
28d 
Fungal Corneal 
ulcer 
Y 
15. 
44 
/M 
Perforated 
corneal 
TCI ND CB 
Perforate
d corneal 
0d 
Fungal Corneal 
ulcer 
Y 
 19 
ulcer ulcer/Y 
16. 
59 
/M 
Fungal 
Keratitis 
TCI 
Fusarium 
spp.  
CB 
Large 
corneal 
ulcer/Y 
1d 
Fungal Corneal 
ulcer 
Y 
17. 
48 
/M 
Microbial 
Keratitis 
3x4 
Aspergillus 
spp.  
CB 
Large 
corneal 
ulcer/Y 
6d 
Fungal Corneal 
ulcer 
NG 
18. 
46 
/M 
Microbial 
Keratitis 
3x2 NG CB 
Large 
corneal 
ulcer/Y 
4d 
Fungal Corneal 
ulcer 
Y 
19. 
54 
/M 
Fungal 
Keratitis 
6x5 
Aspergillus 
spp.  
CB 
Large 
corneal 
ulcer/Y 
4d 
Fungal Corneal 
ulcer 
Y 
20. 
58 
/F 
Microbial 
Keratitis 
3.5x3 
Unid. 
Dematiace
ous 
Fungus  
CB 
Impendin
g 
perforati
on 
/ Y 
2d 
Fungal Corneal 
ulcer 
Y 
21. 
56 
/M 
Fungal 
Keratitis 
10x8 
Fusarium 
spp.  
CB 
Near 
total 
infiltrate/
Y 
9d 
Fungal Corneal 
ulcer 
NG 
22. 
44 
/F 
Microbial 
Keratitis 
7x6 NG CB 
No 
response/
Y 
5d 
Fungal Corneal 
ulcer 
NG 
23. 
44 
/M 
Perforated 
corneal 
ulcer 
TCI ND CB 
Perforate
d corneal 
ulcer/Y 
0d 
Fungal Corneal 
ulcer 
Y 
 
24. 
37 
/F 
Fungal 
Keratitis 
3.5x2.5 
Fusarium 
spp.  
CB 
Resolved 
keratitis/
Y 
7m Corneal scar NG 
25. 
52 
/M 
Fungal 
Keratitis 
TCI 
Burkholder
ia spp.  
CB 
Resolved 
keratitis/
Y 
10m Corneal scar NG 
26. 
26 
/M 
Microbial 
keratitis 
8x5 
pseudo 
allescheria 
boydii  
CB 
Resolved 
keratitis/
Y 
10m Corneal scar NG 
 489 
 490 
 491 
Abbreviations: Inf- infiltrate; M/F- male/female; CB-corneal button; Y-yes; Pres to Ker- duration 492 
between the date of first presentation and date of keratoplasty; d/m/yrs-days/months/years; TCI- total 493 
corneal infiltrate; NG-no growth; NA- not applicable; ND-not done; unid: unidentified; LFU-lost to 494 
follow up; Scr-C/S: Growth of fungus in culture from scraping samples; CB-C/S: Growth of fungus in 495 
culture from corneal button samples, Imp-Impression cytology. 496 
 497 
 498 
 499 
 500 
